{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:50:58Z","timestamp":1793451058658,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda group of companies","award":["NCT01771809"],"award-info":[{"award-number":["NCT01771809"]}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>TURANDOT II was a phase 2, multicentre, open-label [OL] study in patients with moderate-to-severe UC who completed TURANDOT on placebo or ontamalimab (NCT01771809). Patients were randomised to 75 mg or 225 mg ontamalimab every 4 weeks for 72 weeks [OL1]. The dosage could be increased to 225 mg from Week 8 at the investigator\u2019s discretion. All patients then received 75 mg every 4 weeks for 72 weeks [OL2], followed by 6-month safety follow-up. The primary objective was safety, measured by adverse events [AEs], serious AEs [SAEs], and AEs leading to withdrawal. Mucosal healing [MH; centrally read endoscopy] was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 330 patients, 180 completed OL1; 94 escalated to 225 mg; 127 completed OL2. Overall, 36.1% experienced drug-related AEs. The most common SAE [10.0%] was worsening\/ongoing UC; 5.5% of patients had serious infections, the most common being gastroenteritis [0.9%]. One death and four cancers [all unrelated to ontamalimab] occurred. No PML [progressive multifocal leukoencephalopathy]\/lymphoproliferative disorders occurred. Geometric mean high-sensitivity C-reactive protein [hsCRP] and faecal calprotectin decreased across OL1 in both dose groups. The proportion of patients assigned to placebo in TURANDOT achieving MH increased from 8.8% [6\/68] at baseline to 35.3% at Week 16 [24\/68; non-responder imputation]. The corresponding increase in the ontamalimab group was from 23.3% [61\/262] to 26.7% [70\/262].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab023","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T20:27:08Z","timestamp":1613420828000},"page":"938-949","source":"Crossref","is-referenced-by-count":37,"title":["Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II"],"prefix":"10.1093","volume":"15","author":[{"given":"Walter","family":"Reinisch","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Diseases Center, Humanitas University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[{"name":"University of Nice Sophia Antipolis, CHU of Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"K\u0142opocka","sequence":"additional","affiliation":[{"name":"Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Tarabar","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Va\u0148\u00e1sek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Charles University Hospital, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Gregu\u0161","sequence":"additional","affiliation":[{"name":"Gastroenterology Centre, Nitra, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Hellstern","sequence":"additional","affiliation":[{"name":"Gastroenterology, Nature Coast Clinical Research, Inverness, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Sung","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P","family":"Sparrow","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Clinic, Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Gorelick","sequence":"additional","affiliation":[{"name":"Zymo Consulting Group, Newtown Square, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoy","sequence":"additional","affiliation":[{"name":"Shire, a Takeda company, Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Shire, a Takeda company, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Bliss","sequence":"additional","affiliation":[{"name":"Shire, a Takeda company, Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Cytel Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cataldi","sequence":"additional","affiliation":[{"name":"Shire, a Takeda company, Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"2021062213002828800_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2021062213002828800_CIT0002","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/apt.15005","article-title":"Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"48","author":"Paschos","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2021062213002828800_CIT0003","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE]: determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2021062213002828800_CIT0004","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00325481.2017.1319730","article-title":"Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis","volume":"129","author":"Dubinsky","year":"2017","journal-title":"Postgrad Med"},{"key":"2021062213002828800_CIT0005","first-page":"572","article-title":"Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis","volume":"31","author":"Paschos","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2021062213002828800_CIT0006","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/ijms18091973","article-title":"Can we predict the efficacy of anti-TNF-\u03b1 agents?","volume":"18","author":"Lopetuso","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2021062213002828800_CIT0007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2021062213002828800_CIT0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jpge.2015.11.004","article-title":"Anti-TNF withdrawal in inflammatory bowel disease","volume":"23","author":"Torres","year":"2016","journal-title":"GE Port J Gastroenterol"},{"key":"2021062213002828800_CIT0009","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CEG.S150908","article-title":"Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy","volume":"12","author":"Tran","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"key":"2021062213002828800_CIT0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med"},{"key":"2021062213002828800_CIT0011","doi-asserted-by":"crossref","first-page":"19429","DOI":"10.1074\/jbc.272.31.19429","article-title":"Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity","volume":"272","author":"Newham","year":"1997","journal-title":"J Biol Chem"},{"key":"2021062213002828800_CIT0012","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2353\/ajpath.2010.090437","article-title":"CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis","volume":"176","author":"Allavena","year":"2010","journal-title":"Am J Pathol"},{"key":"2021062213002828800_CIT0013","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"2021062213002828800_CIT0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/337179a0","article-title":"The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes","volume":"337","author":"Nakache","year":"1989","journal-title":"Nature"},{"key":"2021062213002828800_CIT0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/331041a0","article-title":"A tissue-specific endothelial cell molecule involved in lymphocyte homing","volume":"331","author":"Streeter","year":"1988","journal-title":"Nature"},{"key":"2021062213002828800_CIT0016"},{"key":"2021062213002828800_CIT0017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1476-5381.2009.00137.x","article-title":"Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody","volume":"157","author":"Pullen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2021062213002828800_CIT0018","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ecco-jcc\/jjx128","article-title":"Effect of PF-00547659 on central nervous system immune surveillance and circulating beta7+ T cells in Crohn\u2019s disease: report of the TOSCA study","volume":"12","author":"D\u2019Haens","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2021062213002828800_CIT0019","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2016-313457","article-title":"Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn\u2019s disease: report of the OPERA study","volume":"67","author":"Sandborn","year":"2018","journal-title":"Gut"},{"key":"2021062213002828800_CIT0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"2021062213002828800_CIT0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody [PF-00547659] for ulcerative colitis [TURANDOT]: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2021062213002828800_CIT0022","article-title":"An electrochemiluminescence [ECL] immunoassay for the detection of anti-drug antibodies against the anti-mucosal addressin cell adhesion molecule [MAdCAM] monoclonal antibody ontamalimab [SHP647]","author":"Wang"},{"key":"2021062213002828800_CIT0023","doi-asserted-by":"crossref","article-title":"Population pharmacokinetics and pharmacodynamics of ontamalimab (SHP647), a fully human monoclonal antibody against mucosal addressin cell adhesion molecule-1 (MAdCAM-1), in patients with ulcerative colitis or Crohn\u2019s disease","author":"Wang","DOI":"10.1002\/jcph.1590"},{"key":"2021062213002828800_CIT0024","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2021062213002828800_CIT0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"2021062213002828800_CIT0026","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"2021062213002828800_CIT0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML","volume":"22","author":"Berger","year":"2016","journal-title":"J Neurovirol"},{"key":"2021062213002828800_CIT0028","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2021062213002828800_CIT0029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-015-0044-2","article-title":"Thrombosis in inflammatory bowel diseases: what\u2019s the link?","volume":"13","author":"Giannotta","year":"2015","journal-title":"Thromb J"},{"key":"2021062213002828800_CIT0030","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1378\/chest.12-1446","article-title":"Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study","volume":"143","author":"Stuijver","year":"2013","journal-title":"Chest"},{"key":"2021062213002828800_CIT0031","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"2021062213002828800_CIT0032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2015.09.001","article-title":"Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"key":"2021062213002828800_CIT0033","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na\u00efve patients with ulcerative colitis","volume":"6","author":"De Vos","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2021062213002828800_CIT0034","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab023\/37380291\/jjab023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/6\/938\/38756626\/jjab023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/6\/938\/38756626\/jjab023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:01:45Z","timestamp":1624366905000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/6\/938\/6144575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,18]]},"published-print":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab023","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,2,18]]}}}